We live in a knowledge economy where a skilled workforce and educated audience are key components to enterprise-wide success. A globally dispersed workforce doesn’t just add logistical challenges to training efforts, it also adds a layer of complexity to the technologies promising to reduce the difficulties faced by learning organizations.
So how are organizations evolving their learning strategies and practices to meet growing global development needs? What technologies have been embrhttp://blog.lionbridge.com/life-sciences/wp-admin/post-new.phpaced by learning leaders and audiences, and what are the greatest challenges to success? Continue reading »
I was recently at a store with my 7 year old son who, seeing a typewriter on the shelf, asked me what it was. I was a little taken aback – how could he not know what it was? I mean, it’s obviously something used to produce written documents, right? “But isn’t that what a computer is for?” came his response. And then I paused… Continue reading »
We’re excited to announce our refreshed website: lifesciences.lionbridge.com
The site has been completely redesigned with our customers and the global life sciences community in mind to better reflect the Lionbridge Life Sciences Difference in who we are, what we do, and in our expanded service offering covering:
These are defining times for life sciences organizations. Emerging and existing markets expand at a rapid pace. The clinical trial landscape broadens. Industry regulations continue to grow in complexity. Customers and communities span the globe, yet are more connected than ever.Some of the goals of the new website were to make it easier to navigate, visually reflective of the life sciences category we solely serve, and– practically speaking, easier for us to update. It’s also responsive, so the new site will work on any computer, tablet, or mobile device. Most of all, we wanted the global life sciences community to get to know us better as to how we can help them meet their language and communication goals. We look forward to feedback from our customers and our industry colleagues on whether our objectives have been achieved!
Now is the time for life sciences companies to partner with a trusted global expert to guide them through the specialized translation and globalization process. One initiative, for example, which relies heavily on collaborating with a trusted, proven partner is in helping an organization move from a decentralized model where translations are managed by local offices– to a centralized one. While quality may be acceptable, a distributed model limits consistency, content efficiency and the organization’s ability to project a single message. The change is undoubtedly challenging, but moving control to the center without losing the benefit of local market insight brings forward many competitive advantages too substantial to ignore. This is one area where Lionbridge Life Sciences excels. Be sure to read our interview—featured on our new home page, about this topic.
A special thanks to all of our customers and advocates around the world who have helped us achieve the enviable position of the #1-ranked language services provider.
Please take a few minutes to explore the site and watch our new video. We would love to hear what you think! As with any new site, we’ll be spending the coming days making certain everything is working as it should. If you find something amiss, please contact me at Kathleen.Bernstein@lionbridge.com
Healthcare marketing professionals work extremely hard developing copy that is creative, engaging and relevant. When it comes time for translation, it is important that the process followed ensures that the messages that took such great effort and time to develop in English, adapt appropriately for the local cultures and languages. There are several options available, and the process recommended depends on the types of assets along with their purposes. Following are brief overviews on the types of processes we at Lionbridge Life Sciences employ to make sure that content is well-adapted and effectively leveraged for global deployment. Continue reading »
It’s hard to go more than a day without hearing news related to the Affordable Care Act (ACA) – commonly referred to as “ObamaCare.” While the national spotlight remains squarely focused on enrollment, coverage policies and technical setbacks on HealthCare.gov, many outside of healthcare circles are less familiar with the influence of new federal mandates on interpretation services. Although the foundation for legal access to various languages was first created in the 1960s, properly providing interpretation services to Limited English Proficient (LEP) patients has been a challenge. Now, the power of the crowd is being leveraged by forward-looking facilities to provide unprecedented, equal and immediate access to even the least commonly spoken of languages. Continue reading »
As I started to write this blog, I was wondering: are we all on the same page with regard to the definition of a “medical device”? Directive 2007/47/EC defines a medical device as “……any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, together with any accessories, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of:
Lionbridge Life Sciences is looking forward to attending the 5th Annual SCOPE Summit, February 4-6 in Miami, Florida. The conference will undoubtedly be a great opportunity for us to hear from industry leaders and discuss with colleagues the topics that impact clinical trial performance. If you’ll be in attendance, please be sure to stop by booth #39 to visit us. Continue reading »
The International Society for Pharmaceutical Engineering (ISPE) recently released the results of its survey collecting feedback from patients on how the clinical trial packaging materials they received during their clinical trial experience impacted them through the trial process. This report and the content covered will likely be met with great interest by those responsible for managing clinical trials, as pharmaceutical companies worldwide continue to struggle with patient compliance/retention. Continue reading »
On the healthcare front, there’s much ground to cover as well in the area of pricing and reimbursement of innovative pharmaceuticals. In Canada, this is controlled at three levels: by the federal Patented Medicine Prices Review Board, by the 17 federal, provincial and territorial public drug plans, and by the Common Drug Review. A pharmaceutical manufacturer must obtain the approval of 19 different bodies for the price of a new drug in Canada. This hurdle presents a big challenge to drug manufacturers and some say impedes Canadians’ access to innovative medicines. Continue reading »
During the Partnerships conference, we’d like to invite you join us on 20.11.2013 at 19.30 to Café Frauenhuber, Vienna’s oldest coffee house to savor delicious coffees and treats and enjoy a relaxed conversation with your peers and colleagues. We’d love to share the research we’ve collected this year from your industry peers about their attitudes regarding global clinical trials, and to determine how Lionbridge Life Sciences can help you with your own future multilingual needs. Please let us know if you’d like to join us at Café Frauenhuber by registering here.